Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

SHA:688578 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,103	674.54	586.99	1,862	470.49	615.36
Short-Term Investments	480	360	280	230	-	20
Trading Asset Securities	2,658	2,511	2,759	419.6	1,567	1,625
Cash & Short-Term Investments	4,241	3,546	3,626	2,512	2,037	2,260
Cash Growth	6.21%	-2.23%	44.37%	23.29%	-9.86%	-12.78%
Accounts Receivable	578.86	375.6	389	260.17	150.85	14.83
Other Receivables	43.29	45.35	29.26	29.07	6.82	3.58
Receivables	622.15	420.96	418.26	289.24	157.68	18.42
Inventory	86.61	71.66	30.56	62.95	32.07	20.8
Prepaid Expenses	-	-	-	-	2.5	-
Other Current Assets	126.11	132.13	105.36	43.97	56.69	75.42
Total Current Assets	5,076	4,170	4,180	2,908	2,286	2,375
Property, Plant & Equipment	501.06	516.92	516.37	526.64	539.94	404.03
Long-Term Investments	3,822	180.49	244.4	145.26	52.73	38.37
Other Intangible Assets	168.37	175.23	65.38	66.49	68.45	67.29
Long-Term Deferred Tax Assets	0	-	0	-	11.5	-
Long-Term Deferred Charges	205.22	176.46	168.12	0.71	0.57	2.11
Other Long-Term Assets	-330.44	2,685	741.45	729.5	482.76	243.79
Total Assets	9,442	7,905	5,916	4,376	3,442	3,130

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	11.57	13.11	27.39	13.25	5.15	1.75
Accrued Expenses	769.2	663.25	482.4	314.33	152.68	96.96
Current Portion of Leases	2.59	1.87	0.99	1.43	1.66	4.72
Current Income Taxes Payable	145.06	101.98	67.45	5.4	6.98	-
Current Unearned Revenue	0.28	4.21	-	-	0.1	0.18
Other Current Liabilities	16.61	21.2	22.37	55.62	88.04	52.51
Total Current Liabilities	945.32	805.62	600.6	390.03	254.62	156.12
Long-Term Leases	1.67	2.01	0.3	0.39	0.3	0.68
Long-Term Deferred Tax Liabilities	29.25	10.57	28.77	0.14	-	-
Other Long-Term Liabilities	3.47	3.27	3.65	3.65	0.2	0.2
Total Liabilities	979.71	821.48	633.32	394.22	255.12	156.99

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	450	450	450	450	450	450
Additional Paid-In Capital	3,284	3,279	3,254	3,175	3,100	3,031
Retained Earnings	4,501	3,230	1,401	264.02	-380.16	-510.68
Comprehensive Income & Other	226.83	123.57	177.89	93.63	17.61	3.25
Shareholders' Equity	8,462	7,083	5,283	3,982	3,187	2,973
Total Liabilities & Equity	9,442	7,905	5,916	4,376	3,442	3,130

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	4.26	3.89	1.3	1.82	1.96	5.39
Net Cash (Debt)	4,236	3,542	3,625	2,510	2,035	2,255
Net Cash Growth	6.20%	-2.30%	44.42%	23.32%	-9.73%	-12.99%
Net Cash Per Share	9.39	7.86	8.06	5.57	4.52	4.94
Filing Date Shares Outstanding	450	450	450	450	450	450
Total Common Shares Outstanding	450	450	450	450	450	450
Working Capital	4,130	3,365	3,580	2,518	2,032	2,219
Book Value Per Share	18.80	15.74	11.74	8.85	7.08	6.61
Tangible Book Value	8,294	6,908	5,217	3,916	3,119	2,906
Tangible Book Value Per Share	18.43	15.35	11.59	8.70	6.93	6.46
Buildings	489.01	489.01	482.3	494.91	470.35	116.73
Machinery	217.43	214.95	182.95	132.04	140.27	88.34
Construction In Progress	1.58	1.21	5.19	18.58	13.8	266.57

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 22, 2026

Data Sources Report a data error